ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0906

Paired Autoantibody Specificities from Serum and Immune Complexes Do Not Fully Explain the Circulating Immune Complex Load in Systemic Lupus Erythematosus: A Study on 530 Patients

Enrico Fuzzi1, Anna Svanqvist2, Christine Westerberg2, Agneta Zickert3, Iva Gunnarsson4, Johan Rönnelid2 and Elisabet Svenungsson5, 1Karolinska University Hospital, Stockholm, Sweden, 2Department of Immunology, Genetics and Pathology, Uppsala University Hospital, Uppsala, Sweden, 3Karolinska University Hospital, Stockholm, Sweden, Stocksund, Sweden, 4Karolinska Institutet, Stockholm, Sweden, 5Department of Medicine Solna, Unit of Rheumatology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

Meeting: ACR Convergence 2023

Keywords: Autoantibody(ies), autoantigens, Biomarkers, immunology, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (0899–0933) SLE – Etiology & Pathogenesis Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic Lupus Erythematosus (SLE) is a prototypical autoimmune disease where autoantibody production and immune complex (IC) formation play a key role. Which antibodies contribute to the load of circulating C1q-binding ICs (CIC) in SLE is still unclear. We investigated whether either serum and/or IC-derived levels of typical SLE antibodies could explain the observed CIC levels of a large SLE cohort.

Methods: We studied n=530 consecutive SLE patients (≥ 4 ACR 1982 revised SLE criteria) who received care at a tertiary referral center for SLE. The control population consisted of region of residence, age and sex-matched controls (n=192) and n=200 local experimental controls. Serum was obtained at inclusion, and was stored at -80°C. To obtain IC-derived antibodies, a novel validated method was employed. Briefly, aliquots of sera were incubated with C1q-coated beads and C1q-bound ICs were then eluted through two sequential buffers, yielding disassembled IC eluates with conserved antibody specificity (Sohrabian et al. Ann Rheum Dis 2018;77:1345). Antibody levels of Anti-dsDNA, Anti-Histone, Anti-Sm, Anti-U1RNP, Anti-Ro52, Anti-Ro60, Anti-SSB were measured in IC eluates and in serum with a bead-based multiplex assay. Parallel analyses of autoantibody levels in serum and in IC eluates were performed. CIC levels were measured with a commercial ELISA according to the manufacturer’s instructions. Results were reported on a standard curve; the 98th percentile of the standard curve values of control sera were set as the threshold for positivity in serum and IC respectively.

Results: CIC levels were higher and with a wider variance in SLE patients than controls (p< 0.0001). A higher CIC load was associated with nephritis, arthritis and SLEDAI > 6 (p< 0.0001). Among autoantibody specificities, Anti-dsDNA in serum was independently associated with a high CIC load (OR 4.8, 95% CI 2.5-9.5, p< 0.0001, Figure 1 A). Concordance between serum and IC-eluate positivity varied strongly among autoantibody specificities, being highest for Anti-SSA/SSB, and lowest for Anti-dsDNA (Table 1). Among serum Anti-dsDNA+ patients, carriers of Anti-dsDNA from ICs displayed higher Anti-dsDNA titers, lower complement levels, and higher SLEDAI scores (p< 0.01 for all, Figure 1 B). Despite this, anti-dsDNA from ICs had a limited, although significant, explanatory power for total CIC levels (Figure 2).

Conclusion: Anti-dsDNA indicates the capacity to assemble immune complexes in SLE patients, and recoverable Anti-dsDNA antibodies from IC eluates are associated with more complement activation and disease activity. Importantly, Anti-dsDNA, either alone or in combination with common ANA specificities, has a limited explanatory power for the variation in CIC levels among different SLE patients, i.e. it is unlikely to form the majority of the observable CIC in SLE. The constituents of the circulating immune complex load in SLE remain elusive and deserve further elucidation.

Supporting image 1

Figure 1 A. and 1 B.

Supporting image 2

Figure 2

Supporting image 3

Table 1


Disclosures: E. Fuzzi: None; A. Svanqvist: None; C. Westerberg: None; A. Zickert: None; I. Gunnarsson: None; J. Rönnelid: None; E. Svenungsson: None.

To cite this abstract in AMA style:

Fuzzi E, Svanqvist A, Westerberg C, Zickert A, Gunnarsson I, Rönnelid J, Svenungsson E. Paired Autoantibody Specificities from Serum and Immune Complexes Do Not Fully Explain the Circulating Immune Complex Load in Systemic Lupus Erythematosus: A Study on 530 Patients [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/paired-autoantibody-specificities-from-serum-and-immune-complexes-do-not-fully-explain-the-circulating-immune-complex-load-in-systemic-lupus-erythematosus-a-study-on-530-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/paired-autoantibody-specificities-from-serum-and-immune-complexes-do-not-fully-explain-the-circulating-immune-complex-load-in-systemic-lupus-erythematosus-a-study-on-530-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology